TARS250117P50000
- 2.50
- -1.75-41.18%
Tarsus Pharmaceuticals Newsroom
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $65
Tarsus Pharmaceuticals Insider Lowered Holding By 16% During Last Year
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's Is How to Trade
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Have Been Lifting Their Price Targets
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $65 to $84
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Tarsus Pharmaceuticals Analyst Ratings
Express News | Tarsus Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $68 From $62
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript Summary
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results.
Tarsus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q3 Revenue $48.1M
Tarsus Pharmaceuticals | 8-K: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Express News | Tarsus Pharmaceuticals Q3 Net Income USD -23.42 Million Vs. IBES Estimate USD -34.8 Million
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Press Release: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Express News | Tarsus Welcomes Kate Goodrich, M.d., Mhs, to Its Board of Directors